JPMorgan Chase & Co. Has $10.68 Million Position in LeMaitre Vascular, Inc. $LMAT

JPMorgan Chase & Co. cut its holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 18.6% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 121,988 shares of the medical instruments supplier’s stock after selling 27,800 shares during the period. JPMorgan Chase & Co.’s holdings in LeMaitre Vascular were worth $10,675,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Tudor Investment Corp ET AL bought a new stake in shares of LeMaitre Vascular during the 3rd quarter valued at about $6,056,000. CIBC Bancorp USA Inc. bought a new stake in LeMaitre Vascular in the third quarter worth approximately $799,000. Advisory Services Network LLC acquired a new position in LeMaitre Vascular in the third quarter valued at approximately $98,000. PharVision Advisers LLC bought a new position in shares of LeMaitre Vascular during the 3rd quarter worth approximately $355,000. Finally, Verition Fund Management LLC boosted its holdings in shares of LeMaitre Vascular by 136.2% during the 3rd quarter. Verition Fund Management LLC now owns 16,907 shares of the medical instruments supplier’s stock worth $1,480,000 after buying an additional 9,750 shares in the last quarter. 84.64% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

LMAT has been the subject of several research analyst reports. Barrington Research lifted their price objective on shares of LeMaitre Vascular from $95.00 to $105.00 and gave the company an “outperform” rating in a research note on Thursday, February 26th. Wall Street Zen raised shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. Zacks Research cut shares of LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a report on Thursday, January 1st. Citizens Jmp lifted their price target on shares of LeMaitre Vascular from $113.00 to $118.00 and gave the company a “market outperform” rating in a research note on Thursday, February 26th. Finally, Weiss Ratings upgraded shares of LeMaitre Vascular from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, March 10th. Four analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $105.80.

Insider Buying and Selling at LeMaitre Vascular

In related news, insider Trent G. Kamke sold 1,044 shares of the company’s stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $110.29, for a total value of $115,142.76. Following the sale, the insider owned 6,677 shares in the company, valued at $736,406.33. This represents a 13.52% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO George W. Lemaitre sold 150,000 shares of the firm’s stock in a transaction dated Thursday, February 26th. The shares were sold at an average price of $106.76, for a total transaction of $16,014,000.00. Following the completion of the transaction, the chief executive officer directly owned 1,532,304 shares in the company, valued at approximately $163,588,775.04. The trade was a 8.92% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 215,438 shares of company stock valued at $23,062,911. Corporate insiders own 9.50% of the company’s stock.

LeMaitre Vascular Trading Down 3.4%

NASDAQ LMAT opened at $106.62 on Friday. The company has a quick ratio of 10.95, a current ratio of 12.89 and a debt-to-equity ratio of 0.43. LeMaitre Vascular, Inc. has a 52 week low of $71.42 and a 52 week high of $115.33. The business has a 50 day moving average price of $96.94 and a 200-day moving average price of $90.11. The company has a market cap of $2.43 billion, a price-to-earnings ratio of 42.48, a P/E/G ratio of 3.07 and a beta of 0.66.

LeMaitre Vascular (NASDAQ:LMAT) last issued its earnings results on Wednesday, February 25th. The medical instruments supplier reported $0.68 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.67 by $0.01. LeMaitre Vascular had a return on equity of 14.72% and a net margin of 23.13%.The company had revenue of $64.45 million for the quarter, compared to analysts’ expectations of $62.98 million. During the same period last year, the business earned $0.49 EPS. LeMaitre Vascular’s quarterly revenue was up 15.7% compared to the same quarter last year. LeMaitre Vascular has set its FY 2026 guidance at 2.810-3.010 EPS and its Q1 2026 guidance at 0.640-0.690 EPS. As a group, equities analysts expect that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 26th. Shareholders of record on Thursday, March 12th were paid a $0.25 dividend. This represents a $1.00 dividend on an annualized basis and a dividend yield of 0.9%. This is a positive change from LeMaitre Vascular’s previous quarterly dividend of $0.20. The ex-dividend date of this dividend was Thursday, March 12th. LeMaitre Vascular’s payout ratio is 39.84%.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.